Abstract

Legend Biotech will report its quarterly results on March 10, 2026 Pre-Market; this preview summarizes last quarter’s metrics and current-quarter forecasts, including revenue, gross margin, net margin, and adjusted EPS, alongside recent institutional commentary from the past six months.

Market Forecast

Based on the company’s latest guidance framework and the aggregated forecast in the financial dataset, Legend Biotech’s current quarter is projected to deliver revenue of $306.87 million with an estimated year-over-year growth of 71.50%, EBIT of -$20.18 million with a year-over-year growth of 75.75%, and adjusted EPS of -$0.11 with a year-over-year growth of 64.00%. The last quarter’s gross margin was 16.11% and the net margin was -14.57%; no company-specific gross or net margin guidance for the new quarter is available in the dataset. The main business continues to be license and collaboration revenue, and the highlight is expected to be durable recognition of partnered revenues from commercial progress; the most promising segment remains license and collaboration, which is forecast to contribute a majority of revenue at $306.87 million, up 71.50% year over year.

Last Quarter Review

Legend Biotech’s previous quarter delivered revenue of $272.33 million, a gross profit margin of 16.11%, GAAP net loss attributable to shareholders of $39.69 million, a net margin of -14.57%, and adjusted EPS of -$0.22, with year-over-year growth for revenue at 69.99% and adjusted EPS improvement of 67.65% compared with the year-ago period. A notable financial highlight was the strong top-line scale driven by recognized license and collaboration revenue, outpacing operating expense growth and reducing adjusted per-share losses versus the prior year. Main business performance remained concentrated in license and collaboration revenue at $272.31 million, implying a 69.99% year-over-year increase, while other revenue was negligible at $0.02 million.

Current Quarter Outlook

Main business: License and collaboration revenue trajectory

The company’s revenue base is dominated by license and collaboration income, which reached $272.31 million last quarter and is forecast at $306.87 million this quarter. The year-over-year forecast acceleration of 71.50% indicates continued momentum in milestone recognition and ongoing partnership economics flowing through the P&L. The profitability profile remains a swing factor because gross margin in the mid-teens limits operating leverage if operating expenses stay elevated, so investors will track whether recognized revenue carries higher-margin components that can lift contribution margins.

Most promising business: Scaling recognized collaboration economics

Forecast data point to license and collaboration revenue as the largest growth engine again, with an implied quarterly increase to $306.87 million and 71.50% year-over-year growth. If execution on planned milestones and commercial ramp continues, the quarter could print near the high end of internal expectations, supporting a sequential uptick from $272.33 million last quarter. Whether EBIT narrows to -$20.18 million and EPS to -$0.11 as forecast will depend on revenue mix and spending cadence across R&D and SG&A tied to partnership development and post-approval support.

Stock price drivers this quarter: Margins, operating spend, and milestone timing

Share performance around the print is likely to be most sensitive to revenue recognition timing for large milestones and to any commentary on the cadence in the second half. Investors will also focus on gross margin expansion from the 16.11% baseline and whether operating expenses allow EBIT to come in near the -$20.18 million forecast, translating to a narrower net loss and an adjusted EPS near -$0.11. Management’s qualitative outlook on collaboration progress and any updates to the revenue trajectory will be critical for sustaining the top-line growth narrative.

Analyst Opinions

Across the past six months of institutional commentary, the majority view leans bullish to cautiously optimistic, highlighting continued year-over-year revenue expansion and improving operating efficiency. Several sell-side notes emphasize that the expected revenue of about $306.87 million and a 71.50% year-over-year increase would represent sustained momentum, while an anticipated narrowing of losses (EBIT at -$20.18 million and adjusted EPS at -$0.11) supports the path toward operating breakeven. The bullish camp underscores that deliverables embedded in collaboration agreements underpin visibility into near-term revenue, and they will watch for margin inflection from the 16.11% gross margin baseline; a minority of more cautious voices cite execution risk around milestone timing and spending requirements, but they remain a smaller share of published views. Overall, the balance of commentary indicates a favorable setup if Legend Biotech can meet or exceed the revenue forecast and demonstrate progress toward margin improvement.